levodopa has been researched along with flibanserin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beck, J; Gerlach, M; Riederer, P; van den Buuse, M | 1 |
| Adamaszek, M; Beck, J; Ohm, S; Schwarz, J; Strecker, K; Wegner, F | 1 |
2 other study(ies) available for levodopa and flibanserin
| Article | Year |
|---|---|
Flibanserin attenuates L: -DOPA-sensitized contraversive circling in the unilaterally 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Benzimidazoles; Disease Models, Animal; Dose-Response Relationship, Drug; Functional Laterality; Levodopa; Male; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Stereotypic Movement Disorder; Time Factors | 2011 |
The 5-HT1A-receptor agonist flibanserin reduces drug-induced dyskinesia in RGS9-deficient mice.
Topics: Animals; Benzimidazoles; Buspirone; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Dyskinesia, Drug-Induced; Exploratory Behavior; Female; Levodopa; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Quinolines; RGS Proteins; Serotonin Antagonists; Serotonin Receptor Agonists | 2012 |